Table 3.
Relationships between genotype and adverse effects
| CYP2D6*10 | CYP2D6*2 | CYP2D6*65 | Statistics | P | |
|---|---|---|---|---|---|
| Weight change from week 0 to 4, kg | −1.2 ± 3.0 | −2.6 ± 2.5 | −13.8 ± 23.4 | 7.514 | 0.001 |
| Weight change from week 0 to 8, kg | −1.6 ± 3.6 | −3.4 ± 2.0 | −1.3 ± 3.8 | 0.798 | 0.455 |
| BMI change from week 0 to 8 | −0.6 ± 1.3 | − 1.3 ± 0.8 | − 0.5 ± 1.3 | 0.985 | 0.380 |
| GLU change from week 0 to 4, mmol/l | − 0.5 ± 1.8 | − 0.3 ± 0.4 | −0.2 ± 2.8 | 0.102 | 0.903 |
| GLU change from week 0 to 8, mmol/l | −0.3 ± 0.8 | −0.6 ± 0.3 | 0.0 ± 1.4 | 0.596 | 0.554 |
| TG change from week 0 to 4, mmol/l | 0.0 ± 1.0 | 0.4 ± 1.1 | −0.2 ± 0.6 | 0.994 | 0.376 |
| TG change from week 0 to 8, mmol/l | −0.1 ± 1.0 | −0.7 ± 1.6 | −0.3 ± 0.7 | 1.800 | 0.175 |
| CHO change from week 0 to 4, mmol/l | −0.3 ± 0.7 | −0.1 ± 0.8 | −0.6 ± 1.1 | 0.984 | 0.379 |
| CHO change from week 0 to 8, mmol/l | −0.2 ± 0.8 | −0.2 ± 0.8 | −1.0 ± 2.0 | 2.395 | 0.100 |
| LDL change from week 0 to 4, mmol/l | − 0.1 ± 0.5 | − 0.1 ± 0.8 | − 0.2 ± 0.5 | 0.964 | 0.387 |
| LDL change from week0 to 8, mmol/l | − 0.1 ± 0.7 | −0.1 ± 0.2 | −0.5 ± 0.7 | 2.631 | 0.081 |
| HDL change from week 0 to 4, mmol/l | −0.1 ± 0.2 | −0.1 ± 0.2 | −0.2 ± 0.2 | 1.041 | 0.359 |
| HDL change from week 0 to 8, mmol/l | 0.0 ± 0.2 | −0.1 ± 0.2 | −0.3 ± 0.5 | 3.366 | 0.042 |
| PRL change from week 0 to 4, mmol/l | 52.1 ± 62.9 | 63.4 ± 63.3 | 72.5 ± 79.8 | 0.509 | 0.603 |
| PRL change from week 0 to 8, mmol/l | 39.4 ± 53.7 | 80.0 ± 65.8 | 95.4 ± 76.1 | 4.359 | 0.017 |
| ESRS week 4 | 8 | 0 | 5 | 5.858 | 0.037 |
| ESRS week 8 | 11 | 1 | 4 | 0.930 | 0.633 |
| BAS week 4 | 5 | 1 | 2 | 0.897 | 0.712 |
| BAS week 8 | 6 | 1 | 1 | 0.493 | 0.632 |
Data are presented as mean ± standard deviation. Abbreviations: BAS Barnes Akathisia Scale, BMI Body mass index, CHO Cholesterol, ESRS Extrapyramidal Symptom Rating Scale, GLU Glucose, HDL High-density lipoprotein, LDL Low-density lipoprotein, PRL Prolactin, TG Triglyceride